Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.311 -0.019 (-1.43%)
Streaming Delayed Price Updated: 12:16 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Analyst Ratings for Fate Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q3 Earnings ↗
 
Via Benzinga
Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
Via Investor Brand Network
News headline image
Analyst Ratings for Fate Therapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Fate Therapeutics ↗
 
Via Benzinga
News headline image
Where Fate Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Fate Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
15 Analysts Have This to Say About Fate Therapeutics ↗
 
Via Benzinga
News headline image
Fate Therapeutics to Present at Upcoming September Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Why Shares of Fate Therapeutics Soared This Week ↗
The company's shares bounced back after a stock sale last week. 
Via The Motley Fool
News headline image
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Fate Therapeutics to Present at Upcoming June Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FATE Long Term Investor Alert: Investigation of Potential Wrongdoing at Fate Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
News headline image
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
$1.7M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed slightly higher on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.